drugset / Trial / NCT06429904
Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, open-label, single arm clinical study. The main purpose of the study is to evaluate the clinical efficacy and safety of Nimotuzumab combined with NALIRIFOX in the treatment of locally advanced pancreatic cancer (LAPC).
Timeline
- Start
- 2024-05-15
- Primary completion
- 2027-05
- Completion
- 2027-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 50 mg/m2 | Intravenous |
| Subject | Leucovorin | Small molecule | 400 mg/m2 | Intravenous |
| Subject | Nimotuzumab | Monoclonal antibody | 400 mg | — |
| Subject | Oxaliplatin | Small molecule | 60 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 2400 mg/m2 | Intravenous |